Crossmark

Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study

Crossref DOI link: https://doi.org/10.1007/s40801-020-00178-8

Published Online: 2020-02-05

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Szerman, Nestor https://orcid.org/0000-0002-9821-7958
Basurte-Villamor, Ignacio https://orcid.org/0000-0001-9898-4105
Vega, Pablo https://orcid.org/0000-0002-6085-8602
Martinez-Raga, Jose https://orcid.org/0000-0002-2856-6562
Parro-Torres, Carlos

Cambra Almerge, Julia https://orcid.org/0000-0002-7381-2136
Grau-López, Lara https://orcid.org/0000-0003-1297-1819
De Matteis, Mario https://orcid.org/0000-0001-9654-9150
Arias, Francisco https://orcid.org/0000-0003-0740-9282
Funding

Funding for this research was provided by:

Otsuka/Lundbeck
License Information

Text and Data Mining valid from 2020-02-05

Version of Record valid from 2020-02-05
More Information

Article History

First Online: 5 February 2020

Change Date: 28 February 2020

Change Type: Correction

Change Details: A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone [29].

Compliance with Ethical Standards

:

: The study was supported by an unrestricted educational grant from Otsuka/Lundbeck to the Fundación de Patología Dual (Madrid, Spain).

: NS has received speaker honorarium from Lundbeck, Shire, Exeltis, Rubio, Indivior, and Adamed: IB-V has received Speaker honorarium from Servier, Exeltis, and Lundbeck; PV has received speaker-travel honorarium from Gilead, MSD, Abbvie, and Rubió. JM-R is advisory board member for Shire and has received speaker honorarium from Lundbeck, Janssen, and Shire; CP-T has received speaker honorarium from Janssen and Servier, and travel grants from Lundbeck and Qualigen; JCA has received travel grants from Lundbeck and Janssen; LG-L has received speaker honorarium from Janssen; MdM has received speaker-travel honorarium from Janssen, Qualigen, Lundbeck; FA declares no conflict of interest related with this manuscript.

: The study was revised and approved by the Ethics Committee of the Hospital General Universitario Gregorio Marañón (Madrid, Spain).

: Informed consent was obtained from all individual participants included in the study.

Updates are available Correction dated 2020-02-28

Click to view Correction: https://doi.org/10.1007/s40801-020-00184-w